Acadia Pharmaceuticals (ACAD) Share-based Compensation (2010 - 2026)

Acadia Pharmaceuticals' Share-based Compensation history runs 17 years deep, the most recent figure standing at $14.7 million for Q1 2026.

• On a quarterly basis, Share-based Compensation rose 29.16% year-over-year to $14.7 million in Q1 2026; TTM through Mar 2026 was $55.5 million, a 12.92% decrease from a year earlier, with the FY2025 full-year figure at $52.1 million, down 22.24% from the prior year.
• Share-based Compensation rose to $14.7 million in Q1 2026 per ACAD's latest filing, from $13.2 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $26.2 million in Q3 2024 and bottomed at -$43.2 million in Q4 2023.
• The 5-year median for Share-based Compensation is $14.7 million (2023), against an average of $12.2 million.
• Across the five-year window, Share-based Compensation sank 399.69% in 2023 and soared 124.19% in 2024, its largest moves.
• Year by year, Share-based Compensation stood at $14.4 million in 2022, then sank by 399.69% to -$43.2 million in 2023, then surged by 124.19% to $10.4 million in 2024, then climbed by 26.65% to $13.2 million in 2025, then climbed by 11.05% to $14.7 million in 2026.
• Per Business Quant, the three latest ACAD Share-based Compensation figures stand at $14.7 million (Q1 2026), $13.2 million (Q4 2025), and $13.2 million (Q3 2025).